Editorial: Transforming growth factor-β: A biomarker in marfan syndrome?

Circulation

Volumn 120, Issue 6, 2009, Pages 464-466

  Braverman, Alan C ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRILLIN 1; LOSARTAN; MATRIX METALLOPROTEINASE; NEBIVOLOL; TRANSFORMING GROWTH FACTOR BETA; BIOLOGICAL MARKER;

CHROMOSOME 15; CLINICAL EVALUATION; CLINICAL FEATURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EDITORIAL; ENZYME ACTIVITY; FOLLOW UP; GENE MUTATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HUMAN; MARFAN SYNDROME; NONHUMAN; ONSET AGE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN INTERACTION; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BLOOD; NOTE;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; MARFAN SYNDROME; TRANSFORMING GROWTH FACTOR BETA;

EID: 69449108394     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.883629     Document Type: Editorial

References (14)

1. Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson CM, Puffenberger EG, Hamosh A, Nanthakumar EJ, Curristin SM, Stetten G, Meyers DA, Francamano CA. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991;352:337-339.
2. Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, Ramirez F, Sakai LY, Dietz HC. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet. 2003;33: 407-411.
3. Ng CM, Cheng A, Myers LA, Martinez-Murillo F, Jie C, Bedja D, Gabrielson KL, Hausladen JM, Mecham RP, Judge DP, Dietz HC. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest. 2004;114:1586-1592.
4. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312:117-121.
5. Goumans MJ, Liu Z, ten Dijke P. TGF-β signaling in vascular biology and dysfunction. Cell Res. 2009;19:116-127.
6. Nagshima H, Sakomure Y, Aoka Y, Uto K, Kameyama Ki, Ogawa M, Aomi S, Koyanagi H, Ishizuka N, Naruse M, Kawana M, Kasanuki H. An angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis in cystic medial degeneration associated with Marfan's syndrome. Circulation. 2001;104:1282-1287.
7. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC III. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med. 2008;358:2787-2795.
8. Lacro RV, Dietz HC, Wruck LM, Bradley TJ, Colan SD, Devereux RB. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losar-tan) in individuals with Marfan syndrome. Am Heart J. 2007;154: 624-631.
9. Yetman AT, Bornemeier RA, McCrindle BW. Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Am J Cardiol. 2005;95:1125-1127.
10. Ahimastos AA, Aggarwal A, D'Orsa KM, Formosa MF, White AJ, Savarirayan R, Dart AM, Kingwell BA. Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial. JAMA. 2007;298:1539-1547.
11. Chung AWY, Yand HHC, Radomski MW, van Breemen C. Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in Marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9. Circ Res. 2008;102:e73-e85.
12. Matt P, Schoenhoff F, Habashi J, Holm T, Van Erp C, Loch D, Carlson OD, Griswold BF, Fu Q, De Backer J, Loeys B, Huso D, McDonnell NB, Van Eyk JE, Dietz HC; GenTAC consortium. Circulating transforming growth factor-β in Marfan syndrome. Circulation. 2009;120:526-532.
13. Faivre L, Collod-Beroud G, Loeys BL, Child A, Binquet C, Gautier E, Callewaert B, Arbustini E, Mayer K, Arslan-Kirchner M, Kiotsekoglou A, Comeglio P, Marziliano N, Dietz HC, Halliday D, Beroud C, Bonithon-Kopp C, Claustres M, Muti C, Plauchu H, Rboinson PN, Ades LC, Biggin A, Benetts B, Brett M, Holman KM, De Backer J, Coucke P, Francke U, De Paepe A, Jondeau G, Boileau C. Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. Am J Hum Genet. 2007;81:454-466.
14. Gambarin FI, Favalli V, Serio A, Regazzi M, Vigano M, Odero A, Tavazzi L, Arbustini E. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 mutations. J Cardiovasc Med. 2009;10:354-362.